Clinical Trials Sponsored by BioActor+B.V.

Total 1426 results

Mach-E B.V.

Completed

Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.

Covid19

United States
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
Equilibre Biopharmaceuticals B.V.

Completed

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

Safety Issues

United States
Ausnutria Hyproca B.V.

Completed

Study of Nutritional Suitability of a New Infant Formula for Term Infants

Growth

Spain, Germany, Croatia, Austria
Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Pantarhei Oncology B.V.

Completed

Evaluation of Safety and Efficacy of Estetrol in Healthy Men

Prostatic Neoplasms

Netherlands
Disphar International B.V.

Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Comparative Bioavailability

Jordan
Disphar International B.V.

Completed

Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Patients With Advanced or Metastatic Solid Tumors
Disphar International B.V.

Withdrawn

Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet

Comparative Bioavailability

Jordan
BBB-Therapeutics B.V.

Terminated

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Multiple Sclerosis | Healthy Volunteers

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Genetic Disorders

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Angioneurotic Edema

Netherlands
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Genetic Disorders | Angioneurotic Edema

Netherlands, Romania
Janssen-Cilag B.V.

Completed

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Anemia | Neoplasm
Maastricht University Medical Center
Scelta Mycofriends B.V.; CNC Grondstoffen B.V.

Recruiting

Agaricus Bisporus and Influenza Vaccination Response

Immune Response

Netherlands
Seaborough Life Science B.V.
University of Groningen; Chrono@Work B.V.

Not yet recruiting

PBM Effects on Health and Well-being in Humans

Sleep Deprivation | Circadian Rhythm Disorders
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

Coronavirus Disease-2019 (COVID-19) Prevention

Mexico, South Africa, Brazil, Argentina, India
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
Janssen Vaccines & Prevention B.V.

Completed

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Human Immunodeficiency Virus

Thailand
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Healthy

Philippines
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States
Medical Enterprises Europe B.V.

Withdrawn

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (SHTC-EUROPE-1)

Neoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms
ATRO Medical B.V.
Avania

Recruiting

AIR (Artificial Implant to Restore the Medial Meniscus Function)2 Clinical Investigation (AIR2)

Knee Injuries and Disorders

Netherlands
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Janssen Vaccines & Prevention B.V.

Terminated

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (CYPRESS)

Respiratory Tract Diseases | Respiratory Syncytial Viruses

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Orthox Limited
Avania B.V.

Terminated

FibroFix Cartilage P Knee Implant Study (FFLEX)

Osteoarthritis, Knee

United Kingdom, Hungary
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
TripleMed B.V.
Fakkel bvba

Completed

ANEUFIX for Endoleaks Type II (ACP-T5)

Abdominal Aortic Aneurysm

Netherlands
Medical Enterprises Europe B.V.

Withdrawn

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Bladder Cancer
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
AbGenomics B.V Taiwan Branch

Terminated

A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant

Acute Graft Versus Host Disease

United States
Revent Medical International B.V.

Completed

Feasibility Study of the ReVENT Sleep Apnea System (REV-001)

Obstructive Sleep Apnea (OSA)
AbGenomics B.V Taiwan Branch

Withdrawn

A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation

United States
AbGenomics B.V Taiwan Branch

Completed

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

United States
Refocus Ocular Europe, B.V.

Completed

Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients

Presbyopia

United Kingdom
AbGenomics B.V Taiwan Branch

Completed

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients (AbGn-168H)

Moderate to Severe Chronic Plaque Psoriasis

United States
Aeon Astron Europe B.V.

Unknown

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany

Open-angle Glaucoma

Germany
Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
BAAT Medical Products B.V.

Recruiting

SINEFIX-2022 Pilot Phase

Rotator Cuff Tears (RCTs)

Germany
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Covid-19 Prevention

Belgium, United States

3

Subscribe